RedHill Biopharma (RDHL) Posts Q1 Loss of 5c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
RedHill Biopharma Reports Results for the First Quarter of 2015
April 30, 2015 7:02 AM EDTKey Highlights Include:
Strong cash position of approximately $32.5 million at the end of the first quarter of 2015, following the closing of the Company's first public offering in the U.S. including participation by leading institutional healthcare investors Key milestones achieved in the first quarter of 2015 included the acquisition of the exclusive worldwide license to ABC294640, a Phase II-stage, proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2) inhibitor from Apogee Biotechnology Corp., targeting multiple oncology and inflammatory-GI diseases Milestones expected in the second quarter of 2015... More